Douglas Adkins, MD
Medical Oncology · Saint Louis, MONPI 1164440616
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,108 of the $141,155 with a category attached, or 77.3%. 17 manufacturers reported payments, led by Merck at 37.1% of the total. Among medical oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $1015.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$52K
- Coherus Oncology, Inc.$14K
- Eisai Inc.$12K
- Regeneron$12K
- Exelixis Inc.$8K
- Genmab U.S., Inc.$6K
- plus $37K from 11 others
Across 873 payments — averaging $21,784 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$10.3M
- Pfizer$3.8M
- Bristol Myers Squibb$1.1M
- E.r. Squibb & Sons, L.L.C.$422K
- Lilly USA, LLC$361K
- Ipsen Biopharmaceuticals, Inc$355K
- plus $2.7M from 29 others
What the payments were for
- Consulting fees$109,10877%
- Speaking & faculty fees$19,81014%
- Travel & lodging$8,9806%
- Food & beverage$3,2462%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 59 | $52,339 |
| Coherus Oncology, Inc. | 7 | $14,308 |
| Eisai Inc. | 11 | $11,672 |
| Regeneron | 16 | $11,578 |
| Exelixis Inc. | 12 | $8,119 |
| Genmab U.S., Inc. | 7 | $5,998 |
| EMD Serono, Inc. | 3 | $5,374 |
| EMD Serono Research & Development Institute, Inc. | 1 | $5,325 |
| GSK | 7 | $5,183 |
| Seagen Inc. | 3 | $4,948 |
| Jazz Pharmaceuticals Inc. | 1 | $3,720 |
| Boehringer Ingelheim International GmbH | 3 | $3,400 |
| Pfizer | 5 | $2,596 |
| Astrazeneca UK Limited | 1 | $2,460 |
| Blueprint Medicines Corporation | 1 | $2,240 |
| Janssen Scientific Affairs, LLC | 1 | $1,763 |
| Gilead | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$141,155 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 38 | $606,017 |
| TafinlarDabrafenib Mesylate | 27 | $352,165 |
| Xtampza ErOxycodone Myristate | 11 | $8,568 |
| Fentanyl | 31 | $3,086 |
| Oxycodone Hcl | 64 | $2,419 |
| Prochlorperazine Maleate | 52 | $1,065 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $938 |
| Minocycline Hcl | 12 | $770 |
| Morphine Sulfate | 15 | $626 |
| Doxycycline Monohydrate | 13 | $612 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $503 |
| Levothyroxine Sodium | 74 | $387 |
| Methadone Hcl | 13 | $361 |
| Dexamethasone | 61 | $294 |
| Prednisone | 105 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $11,672 | $606,01738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
- Bruce RothSaint Louis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.